Capricor Therapeutics

CAPRPre-clinical

Founded 2005capricor.com

Capricor Therapeutics is dedicated to advancing a new class of medicines using its core expertise in cardiosphere-derived cells (CDCs) and exosome science. The company is on the cusp of a potential regulatory milestone with Deramiocel for DMD, supported by positive late-breaking HOPE-3 trial data. Beyond its lead program, Capricor is building a broader pipeline through its StealthX™ platform, targeting the delivery of oligonucleotides, proteins, and small molecules, positioning it at the forefront of precision-engineered exosome therapeutics.

Market Cap

$1.7B

Founded

2005

Focus

BiologicsCell & Gene Therapy

CAPR · Stock Price

USD 29.10+23.42 (+412.32%)

Historical price data

AI Company Overview

Technology Platform

Capricor's core technology is based on allogeneic cardiosphere-derived cells (CDCs) and its proprietary StealthX™ exosome platform, which engineers exosomes for targeted delivery of therapeutic payloads (oligonucleotides, proteins, small molecules) and for use in vaccinology.

Funding History

Total raised: $33M

Grant$3MNIHJun 15, 2021

PIPE$20MUndisclosedDec 15, 2020

Series A$10MUndisclosedJun 15, 2005

Opportunities

The primary near-term opportunity is the successful FDA approval and commercialization of Deramiocel for DMD, a multi-billion dollar rare disease market.

Long-term, the StealthX™ exosome platform offers a vast opportunity to create a pipeline of novel vaccines and targeted therapeutics across multiple disease areas, potentially through high-value partnerships.

Risk Factors

Key risks include regulatory rejection or delay for Deramiocel, challenges in commercializing a rare disease therapy, the preclinical and unproven nature of the StealthX platform, and ongoing dependence on capital markets for funding given the company's pre-revenue status.

Competitive Landscape

In DMD, Capricor competes with gene therapy leaders like Sarepta Therapeutics and Pfizer. Deramiocel differentiates by targeting inflammation and fibrosis. In the exosome space, it faces emerging competition from biotechs like Codiak and Evox, requiring its StealthX platform to demonstrate superior targeting, payload, and manufacturing capabilities.

Publications

Patents